METHOD FOR PREDICTING IN VITRO RESPONSIVENESS OF SUBJECT TO ANTI PD-1 ANTIBODY

• Main Authors: HAMADA YUKI, OKAWA MASASHI, TAGAMI KIYONORI, OTSUKA TAKAO, YAMADA SHINGO, HASHIGUCHI TERUTO, MATSUSHITA DAISUKE, YAMAGUCHI SOICHI, ARIGAMI TAKAAKI, TAKENOUCHI KAZUNORI
• Format: Patent
• Language: English; Japanese
• Published: 28.05.2025
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

To provide a method for predicting treatment responsiveness in a cancer patient who receives treatment with an anti PD-1 antibody (especially, Nivolumab).SOLUTION: Provided is a method for predicting in vitro the responsiveness of a subject to an anti PD-1 antibody, and the method includes: a measurement step of measuring the amount of VEGF-A121 protein and the amount of VEGF-A165 protein in a sample derived from the subject; and a prediction step of predicting the responsiveness of the subject to treatment with the anti PD-1 antibody, on the basis of a ratio calculated from the measured amounts of two types of protein.SELECTED DRAWING: Figure 7D 【課題】抗ＰＤ－１抗体（特にニボルマブ）による治療を受ける癌患者における治療応答性を予測する方法を提供する。【解決手段】被験者の抗ＰＤ－１抗体に対する応答性をｉｎ ｖｉｔｒｏで予測するための方法であって、前記被験者由来の試料中におけるＶＥＧＦ－Ａ１２１タンパク質の量及びＶＥＧＦ－Ａ１６５タンパク質の量を測定する測定工程、及び測定された前記２つのタンパク質の量から算出される比率に基づいて、前記被験者の抗ＰＤ－１抗体による治療に対する応答性を予測する予測工程、を含む方法。【選択図】図７Ｄ